The Mounjaro Divide: Unveiling a Growing Health Inequality
In a world where access to healthcare should be equitable, a new challenge has emerged, creating a stark divide between those who can afford better health and those who are left struggling. Meet Kelly Todd, a 46-year-old who, four years ago, embarked on a journey to manage her weight through the NHS. She soon realized that the road to obtaining the necessary weight-loss drugs was long and winding, leading her to explore private options.
But here's where it gets controversial... While the NHS introduced GLP-1 drugs like Mounjaro last year, the criteria for access are stringent, favoring those with a BMI over 40 and multiple weight-related complications. Todd, despite her efforts, is still waiting, having effectively spent over four years navigating the NHS system.
"The uncertainty is frustrating. I've been waiting for years, and it doesn't feel like a realistic option to continue indefinitely without support," she shares.
Todd's story is not unique. Research reveals a disturbing trend: weight loss jabs are more commonly used by middle-class women in their thirties and forties, leaving those in the most deprived areas at a disadvantage.
The Health Foundation, in collaboration with Voy, analyzed private prescriptions for GLP-1 drugs and found a startling reality: 79% of these prescriptions are for women willing to spend hundreds of pounds each month. Furthermore, individuals from deprived areas are a third less likely to access these jabs and often start the medication at a much higher weight, creating a significant class divide with profound health consequences.
"This is a familiar phenomenon in public health," explains Kate Pickett, Professor of Epidemiology at York University. "It's intervention-generated inequality. Middle-class and wealthy individuals often have an easier time understanding and accessing these interventions, leading to improved health but also widening the inequality gap."
And this is the part most people miss... Last year, NICE stated that GLP-1 drugs should be available to anyone with a BMI over 35 and one weight-related comorbidity, affecting 3.4 million people. However, NHS England took an unusual step, limiting access to only 220,000 people over three years, raising the threshold to a BMI over 40 and four comorbidities.
The problem? Not everyone will receive the drug due to availability constraints, leaving them with a private option costing £144-£324 monthly. Kelly Todd, who had to leave her job due to health reasons, made the choice to go private, aware that not everyone can afford this.
"It's a conscious choice to invest in my health, but it comes with sacrifices," she says. "The disparity is significant, and it feels like a lottery. Eligibility doesn't guarantee access."
Dr. Charlotte Refsum, Director of Health Policy at the Tony Blair Institute for Global Change, believes the current Mounjaro rollout "risks entrenching health inequality."
"Those with wealth can buy better health and life chances, while others are left behind. This goes against the NHS's founding principle of care based on need, not ability to pay," she asserts.
But the issue extends beyond the class health divide. There's a concern that the "Mounjaro gap" could revive the notion that being thin is associated with status and wealth, a trend that the body positivity movement had aimed to dismantle.
"We've moved away from that mindset, but people worry the pendulum is swinging back," Pickett says. "Class-related differences in body shape may become entrenched, reinforcing the idea that 'you can never be too rich or too thin.'"
Pickett also highlights the existence of private providers offering these drugs to individuals with a BMI of 30 and above, not just those clinically obese, but to those with an aesthetic desire, not a medical need.
Field, on the other hand, is optimistic, believing that "being thin may become less desirable once it's easier to achieve." However, she is concerned about weight-loss drugs widening life expectancy gaps based on class and gender.
"These drugs significantly impact health outcomes, and we already have a 20-year gap in healthy life expectancy between the richest and poorest. The government aims to halve this, but these trends in the private sector make it challenging to see how they'll achieve that," she explains.
Dr. Refsum emphasizes the need for the NHS to take a bolder approach, suggesting the offer of anti-obesity medications to adults with a BMI of 27 and above, with no major contraindications, over the next two years. This would mean rolling out these medications to an estimated 14.7 million people, not just a small fraction.
"The NHS needs to adapt and move faster to keep up with medical advances that can improve outcomes and prevent long-term illness. We must think boldly about widening access, from digital support to offering treatment when patients need it most, ensuring these innovations reduce, not deepen, health inequalities."
So, what do you think? Is the Mounjaro gap a symptom of a deeper issue within our healthcare system? Should the NHS take a more proactive approach to prevent health inequalities? We'd love to hear your thoughts in the comments below!
